MétaCan
Menu
Back to cohort
Record W2549622127 · doi:10.1093/ofid/ofw172.1058

A Pilot Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients

2016· article· en· W2549622127 on OpenAlexaff
Yoichiro Natori, Atul Humar, Jeffrey H. Lipton, Dennis Kim, Katja Höschler, Peter D. Ashton, Deepali Kumar

Bibliographic record

VenueOpen Forum Infectious Diseases · 2016
Typearticle
Languageen
FieldMedicine
TopicInfluenza Virus Research Studies
Canadian institutionsUniversity Health Network
Fundersnot available
KeywordsMedicineStem cellHematopoietic stem cellHematopoietic stem cell transplantationRandomized controlled trialImmunologyHaematopoiesisInternal medicineTransplantationVirology

Abstract

fetched live from OpenAlex

Background. The annual influenza vaccine is recommended for hematological stem cell transplant (HSCT) recipients, although studies have shown suboptimal immunogenicity for the standard vaccine. Influenza vaccine containing an oil-in-water emulsion adjuvant (MF-59) may lead to greater immunogenicity in hematological stem cell transplant recipients. Methods. We conducted a randomized controlled trial comparing the safety and immunogenicity of adjuvanted versus nonadjuvanted influenza vaccine in adult allogeneic HSCT patients. Patients who were ≥12 weeks post-transplant were randomized 1:1 to receive the 2015–2016 influenza vaccine with or without MF59 adjuvant. Both vaccines contained 15 µg each of A/California/7/2009 (H1N1)pdm09, A/Switzerland/9715293/2013 (H3N2), and B/Phuket/3073/2013. Preimmunization and 4-week postimmunization sera underwent strain-specific hemagglutination inhibition assay. Results. We randomized 73 patients and 67 (35 adjuvanted; 32 nonadjuvanted) had complete samples available at follow-up. Median age was 54 years (range 22–74) and time from transplant was 380 days (range 85–8107). Concurrent graft versus host disease (GVHD) occurred in 42/73 (57.5%). Baseline seroprotection rates were 47.8%, 46.3%, and 43.3% for A/H1N1, A/H3N2, and B, respectively. Seroconversion to at least 1 of 3 influenza antigens was present in 62.9% versus 53.1% for adjuvanted versus nonadjuvanted vaccine, respectively (P = 0.42). Seroconversion to A/H1N1, A/H3N2, and B was 31.4% versus 21.9%, 57.1% versus 40.6%, and 37.1% versus 25.0% in adjuvanted versus nonadjuvanted vaccine (P = 0.38, 0.18, 0.29), respectively. Pre- and post-vaccination geometric mean titers were similar between groups. Factors associated with lower seroconversion rates were antithymoglobulin usage within one year (P = 0.03), use of calcineurin inhibitors (tacrolimus or cyclosporine) (P < 0.001), and shorter duration from transplantation (P < 0.001). Seroconversion rates were greater in patients who received previous year influenza vaccination (82.6% versus 45.5%, P = 0.03). Concurrent GVHD was not associated with vaccine response (P = 0.25). Local and systemic adverse events were similar for the two vaccines. Conclusion. Adjuvanted vaccine demonstrated similar immunogenicity to nonadjvuanted vaccine in allogeneic HSCT patients and may be an option for this population. Disclosures. A. Humar, Roche: Grant Investigator, Research grant D. Kumar, Roche: Grant Investigator, Research grant GSK: Grant Investigator, Research grant Sanofi-Pasteur: Scientific Advisor, Speaker honorarium

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.043
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0040.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.034
GPT teacher head0.335
Teacher spread0.302 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueOpen Forum Infectious DiseasesSame topicInfluenza Virus Research StudiesFrench-language works237,207